Drug – bio-affecting and body treating compositions – Extract – body fluid – or cellular material of undetermined... – Hemic or immune system
Reexamination Certificate
2011-02-22
2011-02-22
Belyavskyi, Michail A (Department: 1644)
Drug, bio-affecting and body treating compositions
Extract, body fluid, or cellular material of undetermined...
Hemic or immune system
C424S809000, C435S372000, C514S885000
Reexamination Certificate
active
07892578
ABSTRACT:
The inventors have discovered that hematologic disorders, e.g., both neoplastic (hematologic cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example, significant graft-versus-leukemia (GVL) effect and the like.
REFERENCES:
patent: 4281061 (1981-07-01), Zuk et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 5004681 (1991-04-01), Boyse et al.
patent: 5192553 (1993-03-01), Boyse et al.
patent: 5484612 (1996-01-01), Brown
patent: 5635156 (1997-06-01), Ildstad
patent: 5730979 (1998-03-01), Bazin et al.
patent: 5834266 (1998-11-01), Crabtree et al.
patent: 6558662 (2003-05-01), Sykes et al.
patent: WO-89/04168 (1989-05-01), None
patent: WO-93/13785 (1993-07-01), None
patent: WO-94/20619 (1994-09-01), None
patent: WO-95/03062 (1995-02-01), None
patent: WO-95/11692 (1995-05-01), None
patent: WO-95/26740 (1995-10-01), None
patent: WO-96/06165 (1996-02-01), None
patent: WO-97/41863 (1997-11-01), None
patent: WO-98/20932 (1998-05-01), None
Maraninchi et al, “Outcome of Allogeneic Bone-Marrow Transplantation for Standard-Risk Leukaemias,”Lancet2:175-178 (1987).
Atkinson et al., “CD4+T cells appear capable of initiating graft-versus-host disease across non-major histocompatibility complex (MHC) barriers in man,”Bone Marrow Transplantation2:79-84 (1987).
Aizawa et al., “Graft-Versus-Leukemia Effect in MHC-Compatible and -Incompatible Allogeneic Bone Marrow Transplantation of Radiation-Induced, Leukemia-Bearing Mice,”Transplantation52:885-9 (1991).
Anasetti et al., “Effect of HLA Compatibility on Engraftment of Bone Marrow Transplants in Patients with Leukemia of Lymphoma,”N Engl. J. Med. 320:197-204 (1989).
Baum et al., “Isolation of a candidate human hematopoietic stem-cell population,”Proc. Natl. Acad. Sci. USA89:2804-8 (1992).
Baurmann et al., “Kinetics of the Graft-Versus-Leukemia Response After Donor Leukocyte Infusions for Relapsed Chronic Myeloid Leukemia After Allogeneic Bone Marrow Transplantation,”Blood92:3582-3590 (1998).
Chopra et al., “Autologous Versus Allogeneic Bone Marrow Transplantation for Non-Hodgkin's Lymphoma: A Case-Controlled Analysis of the European Bone Marrow Transplant Group Registry Data,”J. Clin. Onc. 10:1690-95.
Clift et al., “Histoincompatible Bone Marrow Transplants in Humans,”Ann. Rev. Immunol. 5:43-64 (1987).
Emerson, “Ex Vivo Expansion of Hematopoietic Precursors, Progenitors and Stem Cells: The Next Generation of Cellular Therapeutics,”Blood87:3082-88 (1996).
Fleischhauer et al., “Bone Marrow-Allograft Rejection by T Lymphocytes Recognizing a Single Amino Acid Difference in HLA-B44”N Engl. J. Med. 323(26):1818-22 (1990).
Giralt et al., “Engraftment of Allogeneic Homeopoietic Progenitor Cells with Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia without Myeloablative Therapy,”Blood89:4531-36 (1997).
Giralt et al., “Induction of graft-versus-leukemia (GVL) as primary treatment of chronic myelogenous leukemia (CML),”Blood90:418a (1997).
Henslee-Downey et al., “Combined in Vitro and in Vivo T Lymphocyte Depletion for the Control of Graft-Versus-Host Disease Following Haploidentical Marrow Transplant,”Transplantation61:738-745 (1996).
Henslee-Downey et al., “Use of Partially Mismatched Related Donors Extends Access to Allogeneic Marrow Transplant,”Blood89:3864-3872 (1997).
Ilstad et al., “Effect of Selective T Cell Depletion of Host and/or Donor Bone Marrow on Lymphopoietic Repopulation, Tolerance and Graft-vs-Host Disease in Mixed Allogeneic Chimeras (B10+B10.D2−B10),”J. Immunology, 136:28-33 (1986).
Ilstad et al., “Reconstitution with syngenic plus allogeneic or xenogenic bone marrow leads to specific acceptance of allografts or xenografts,”Nature307:168-70 (1984).
Johnson et al., “Delayed infusion of normal donor cells after MHC-matches bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease,”Bone Marrow Transplantation11:329-36 (1993).
Kawai et al., “Mixed Allogeneic Chimerism and Renal Allograft Tolerance in Cynomolgus Monkeys,”Transplantation59:256-62 (1995).
Khouri et al., “Transplant-Lite: Induction of Graft-Versus-Malignancy Using Fludarabine-Based Nonablative Chemotherapy and Allogeneic Blood Progenitor-Cell Transplantation as Treatment for Lymphoid Malignancies,”J. Clinical Oncology16:2817-24 (1998).
Kolb et al., “Adoptive Immunotherapy in Canine Chimeras,”Transplantation63:430-436 (1997).
Lansdorp et al., “Selective Expression of CD45 Isoforms on Functional Subpopulations of CD34+ Hemopoietic Cells from Human Bone Marrow,”J. Exp. Med. 172:363-66 (1990).
Lapierre et al., “The gel test: a new way to detect red cell antigen-antibody reactions,”Transfusion30:109-113 (1990).
Lenschow et al., “Long-Term Survival of Xenogenic Pancreatic Islet Grafts Induced by CTLA4Ig,”Science, 257:789-792 (1992).
Lundberg et al., “Allogeneic Bone Marrow Transplantation for Relapsed and Refractory Lymphoma Using Genotypically HLA-Identical and Alternative Donors,”J. Clin. Oncol. 9:1848-59 (1991).
Mackinnon et al., “Adoptive Immunotherapy Evaluating Escalating Doses of Donor Leukocytes for Relapse of Chronic Myeloid Leukemia After Bone Marrow Transplantation: Separation of Graft-Versus Leukemia Response From Graft-Versus-Host Disease,”Blood86:1261-1268 (1995).
Nakao et al., “Analysis of late graft failure after allogeneic bone marrow transplantation: detection of residual host cell using amplification of variable number of tandem repeats loci,”Bone Marrow Trans. 9:107-111 (1992).
Nikolic et al., “Bone marrow chimerism and transplantation tolerance,”Current Opinion in Immun. 9:634-40 (1997).
Nikolic et al., “Mixed Hematopoietic, Chimerism and Transplantation Tolerance,”Immun. Res. 16(3):217-28 (1997).
O'Reilly et al., “Transplantation of Marrow Depleted T Cells b Soybean Lectin Agglutination and E-Rosette Depletion: Major Histocompatibility Complex-Related Graft Resistance in Leukemic Transplant Recipients,”Transplantation Proceedings, 17:455-59 (1985).
Petzer et al., “Self-renewal of primitive human hematopoietic cells (long-term culture-initiating cells) in vitro and their expansion in defined medium,”Proc. Natl. Acad. Sci. USA93:1470-74 (1996).
Porter et al., “Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia of myelodysplasia after allogeneic bone marrow transplantation,”Bone Marrow Transplantation18:975-725-49 (1995).
Preffer, “Flow Cytometry,”Diagnostic Immunopathology, Second Edition, Raven Press, Ltd., New York, pp. 725-749 (1995).
Ratanatharathorn et al., “Prospective Comparative trial of Autologous Versus Allogeneic Bone Marrow Transplantation in Patients with Non-Hodgkin's Lymphoma,”Blood84:1050-55 (1994).
Sato et al., “Purification of Human Marrow Progenitor Cells and Demonstration of Direct Action of Macrophage Colony-Stimulating Factor on Colony Forming Unit-Macrophage,”Blood78:967-74 (1991).
Schwartz et al., “Strategy to Detect Chimerism in Allogeneic Bone Marrow Transplant Recipients by PCR-Amplification Fragment Length Polymorphism Analysis of Microsatellite Polymorphisms,”Vox Sanguinis68:139-43 (1995).
Sharabi et al., “Mixed Chimerism and Permanent Specific Transplantation Tolerance Induced by a Nonlethal Preparative Regimen,”J. Exp. Med. 169:493-502 (1989).
Slavin et al., “Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation Wit
Spitzer Thomas R.
Sykes Megan
Belyavskyi Michail A
Fish & Richardson P.C.
The General Hospital Corporation
LandOfFree
Treatment of hematologic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of hematologic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of hematologic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2649491